Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2130 - Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinoma


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Pancreatic Cancer


Michele Reni


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


M. Reni1, S. Zanon1, G. Balzano2, R. Castoldi2, A. Zerbi3, M.C. Tronconi4, D. Pinelli5, S. Mosconi6, C. Doglioni7, M. Falconi2, L. Gianni1

Author affiliations

  • 1 Medical Oncology, IRCCS San Raffaele Scientific Institute, 20132 - Milan/IT
  • 2 Surgery, IRCCS San Raffaele Scientific Institute, 20132 - Milan/IT
  • 3 Pancreatic Surgery, Humanitas Clinical and Research Center, 20089 - Rozzano/IT
  • 4 Cancer Center, Humanitas Clinical and Research Center, 20089 - Rozzano/IT
  • 5 Surgery, "Papa Giovanni XXIII" Hospital, 24127 - Bergamo/IT
  • 6 Oncology, "Papa Giovanni XXIII" Hospital, 24127 - Bergamo/IT
  • 7 Pathology, IRCCS San Raffaele Scientific Institute, 20132 - Milan/IT


Abstract 2130


Pancreatic ductal adenocarcinoma (PDAC) has a remarkable trend to metastasize early. Accordingly, there is a strong rational to investigate preoperative chemotherapy in patients with resectable disease. We conducted a multicenter randomized phase 2 trial (PACT-15; NCT01150630) to assess the role of combination chemotherapy in perioperative setting.


Treatment-naïve patients with 18-75 yr, KPS>60 and pathologically confirmed stage 1-2 resectable PDAC were randomized to surgery followed by 6 cycles of adjuvant gemcitabine 1000 mg/m21,8,15q4w (arm A), or PEXG (cisplatin 30 mg/m2, epirubicin 30 mg/m2, and gemcitabine 800 mg/m2 1,15q4w and capecitabine 1250 mg/m2/day 1-28) (arm B), or to 3 cycles of PEXG before and 3 after surgery (arm C). The primary endpoint was 1-year event-free survival (EFS); the secondary endpoints were EFS, overall survival (OS), and the difference in pathological findings between arm A+B and arm C. With 24 eligible patients in each group (H0 20%, H1 40%, α 10%, β 20%), ≤16 events of 24 would support further evaluation of experimental therapy.


Between September 2010 and April 2015, 88 eligible patients were randomized in 9 Italian centers (arm A: 26, B: 30, C: 32). Basal patients and tumor characteristics were well balanced across arms. One-year EFS (A, B, C) was 6/26 (23%), 15/30 (50%), 23/32 (72%). Median EFS was 4.8, 12.4, 18.9 months (A vs C p=0.002). Three-year OS (A,B,C) was 35%, 42%, 55%. Median OS (A,B,C) was 20.4, 25.1, not reached at 33 months (A vs C p = 0.022). Pathological results are summarized in the table. Treatment safety profile was good.Table:

736P Pathological findings

T resection49 (88%)27 (84%)
Intraoperative metasteses7/56 (13%)2/32 (6%)
Postoperative metastases10/56 (18%)3/32 (9%)
Grade 329/49 (59%)6/27 (22%)
T12/49 (4%)4/27 (15%)
No13/49 (27%)13/27 (48%)
Ro16/49 (33%)15/27 (56%)
Median size2.5 cm2.0 cm


Patients receiving perioperative chemotherapy had significant improvement of EFS and OS as compared to those receiving adjuvant treatment. This trial provides the strongest piece of evidence currently available in favor of preoperative chemotherapy in resectable PDAC.

Clinical trial identification


Legal entity responsible for the study

IRCCS San Raffaele Scientific Institute, Milan, Italy


IRCCS San Raffaele Scientific Institute, Milan, Italy


M. Reni: Funding from Celgene, Baxalta, Helsinn, and Merck-Serono; consultant or advisor for Celgene, Baxalta, Merck Serono, Boheringer, Lilly, Pfizer, AstraZeneca, Novocure, Genentech, Halozyme, Novartis. G. Balzano: Advisory role for Celgene. M. Falconi: Research funding to institution from Novartis. L. Gianni: Consulting/advisory role for Roche, Pfizer, GlaxoSmithKline, Synthon, Taiho Pharmaceutical, AstraZeneca, Genomic Health, Merck Sharp & Dohme, Boehringer Ingelheim, Tiziana Pharma, Synaffix, Celgene; patents/royalties/intellectual property with Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.